Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC

Neal Shore • 21 May 2020
ASCO 2020
Genitourinary Cancer Prostate Cancer Apalutamide Darolutamide Enzalutamide

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) using matching-adjusted indirect comparisons. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Neal Shore

0:56
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
Neal Shore • 26 Jan 2024
0:51
OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS
Neal Shore • 26 Jan 2024
0:44
PROpel: gene-by-gene efficacy of olaparib and abiraterone in mCRPC
Neal Shore • 26 Jan 2024
0:39
TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPC
Neal Shore • 26 Jan 2024

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals